PeptidePedia
Experimental

Selank

A Russian-developed heptapeptide analog of tuftsin studied as a nasal anxiolytic with minimal sedation in small clinical trials.

In plain English

Selank is a synthetic heptapeptide developed in the Russian Federation in the 1990s based on the immune-active tetrapeptide tuftsin. It is administered intranasally and has been studied primarily in Russian clinical trials for generalized anxiety disorder and adjustment disorders. Reported effects include reduction in anxiety symptoms without the sedation, cognitive impairment, or dependence associated with benzodiazepines. Selank is registered as a medicine in Russia but is not approved by the FDA. It is widely sold internationally as a research peptide.

What it is

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg) with a C-terminal extension that increases stability.

Mechanism (summary)

Proposed mechanisms include modulation of GABAergic and serotonergic signaling, influence on brain-derived neurotrophic factor (BDNF), and effects on enkephalinase activity. Detailed mainstream pharmacology is limited.

Why people research it

  • Generalized anxiety disorder
  • Adjustment disorders and stress reactions
  • Cognitive performance under stress
  • Withdrawal-related anxiety

Human evidence

Small Russian-language clinical trials report anxiolytic effects on par with low-dose benzodiazepines without sedation. Independent, large, English-language RCTs are not available.

Animal / lab evidence

Rodent studies describe anxiolytic effects in standard behavioral models (elevated plus maze, open field) and modulation of stress-related neurotransmitters.

Key studies

Each summary explains the design, what was found, and what it doesn't prove.

Human RCT2005·Adults with generalized anxiety disorder
Comparative clinical study of the anxiolytic agent Selank vs. medazepam in generalized anxiety disorder

In a small Russian study, Selank reduced anxiety as well as a benzodiazepine — but without the same sleepiness.

Finding: Selank produced anxiolytic effects comparable with medazepam without sedative side effects in a small comparison trial.
Limitations: Small Russian trial; not blinded against placebo in some arms; methodologic limitations.
Human observational2015·Adults with anxiety disorders
Selank effects on serum BDNF in anxiety disorders

People with anxiety disorders showed changes in a brain-growth protein (BDNF) after using Selank.

Finding: Selank administration was associated with changes in serum BDNF in adults with anxiety.
Limitations: Small observational study, no placebo arm.

History

Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Institute of Pharmacology.

Important:

PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.

Related peptides